A fundamental question in addiction biology is why opiate alkaloid drugs such as morphine and heroin have a high liability for inducing tolerance and addiction while endorphins and enkephalins, the native peptide ligands for opioid receptors, do not. Following activation by agonists, opioid receptors are regulated by multiple mechanisms. Of these regulatory mechanisms, rapid endocytosis of opioid receptors is of particular interest because it is differentially regulated by peptide agonists and alkaloid drugs. Specifically, endogenous opioid peptides and certain opiate drugs such as etorphine and methadone stimulate the rapid internalization of mu opioid receptors. Morphine however, strongly activates receptor signaling but fails to stimulate the rapid internalization of mu opioid receptors. Furthermore, following endocytosis, individual receptors can be sorted differentially between recycling endosomes and lysosomes. This sorting mechanism can contribute to receptor regulation in two ways that have opposing effects on cell signaling. First, endocytosis can serve as a mechanism for receptor resensitization by delivering internalized receptors to endosomes from where they are recycled to the plasma membrane in a fully active state. Second, rapid internalization can serve as a first step toward receptor downregulation by delivering the receptors to endosomes from which they are sent to lysosomes for degradation. Hence for each receptor/ligand pair, one must evaluate both the endocytic and post-endocytic properties. We have generated mutant mu opioid receptors with altered endocytic and post- endocytic trafficking properties. Here we propose to utilize these mutant receptors to assess the molecular and behavioral effects of altered trafficking on the development of tolerance, withdrawal, and addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA019958-05
Application #
8049689
Study Section
Synapses, Cytoskeleton and Trafficking Study Section (SYN)
Program Officer
Pilotte, Nancy S
Project Start
2007-05-01
Project End
2013-06-30
Budget Start
2011-04-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$116,535
Indirect Cost
Name
Ernest Gallo Clinic and Research Center
Department
Type
DUNS #
173995366
City
Emeryville
State
CA
Country
United States
Zip Code
94608
Johnson, Tyler A; Milan-Lobo, Laura; Che, Tao et al. (2017) Identification of the First Marine-Derived Opioid Receptor ""Balanced"" Agonist with a Signaling Profile That Resembles the Endorphins. ACS Chem Neurosci 8:473-485
Milan-Lobo, Laura; Enquist, Johan; van Rijn, Richard M et al. (2013) Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism. PLoS One 8:e58362
Madhavan, Anuradha; Argilli, Emanuela; Bonci, Antonello et al. (2013) Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area. J Neurosci 33:12329-36
van Rijn, Richard M; Harvey, Jessica H; Brissett, Daniela I et al. (2013) Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. J Pharmacol Exp Ther 344:179-88
He, Congcong; Wei, Yongjie; Sun, Kai et al. (2013) Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism. Cell 154:1085-1099
Harvey, Jessica H; van Rijn, Richard M; Whistler, Jennifer L (2013) A FLIPR assay for evaluating agonists and antagonists of GPCR heterodimers. Methods Mol Biol 995:43-54
van Rijn, Richard M; Defriel, Julia N; Whistler, Jennifer L (2013) Pharmacological traits of delta opioid receptors: pitfalls or opportunities? Psychopharmacology (Berl) 228:1-18
Brissett, D I; Whistler, J L; van Rijn, R M (2012) Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes. Eur J Pain 16:327-37
van Rijn, Richard M; Brissett, Daniela I; Whistler, Jennifer L (2012) Emergence of functional spinal delta opioid receptors after chronic ethanol exposure. Biol Psychiatry 71:232-8
Enquist, Johan; Ferwerda, Madeline; Milan-Lobo, Laura et al. (2012) Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice. J Pharmacol Exp Ther 340:386-92

Showing the most recent 10 out of 24 publications